User profiles for S. Bilic

Snezana Bilic

Professor of Economics and Management, International Balkan University, Skopje, North …
Verified email at ibu.edu.mk
Cited by 267

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies

…, S Li, R Schmitz, H Heine, S Bilic… - Proceedings of the …, 2010 - National Acad Sciences
Disregulated Wnt/β-catenin signaling has been linked to various human diseases, including
cancers. Inhibitors of oncogenic Wnt signaling are likely to have a therapeutic effect in …

A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory …

…, KR Kelly, R Isaacs, S Bilic, S Sen… - British journal of …, 2014 - Wiley Online Library
… No DLT s were reported, therefore, the MTD was not determined. The recommended Phase
II dose was declared as 10 mg/kg, based mainly on saturation data. There was a general …

Bioanalysis of antibody–drug conjugates: american association of pharmaceutical scientists antibody–drug conjugate working group position paper

…, S Bilic, B Booth, S Kaur, P Oldfield, S Purushothama… - Bioanalysis, 2013 - Future Science
… Investigations revealed that the method’s ability to detect total antibody with different DAR
depends on the assay format – certain assay formats have reduced sensitivity to the DAR and …

Country‐level correlates of the dark triad traits in 49 countries

…, HY Bundhoo, S Bălțătescu, S Bilić… - Journal of …, 2020 - Wiley Online Library
Objectives The Dark Triad traits (ie, narcissism, psychopathy, Machiavellianism) capture
individual differences in aversive personality to complement work on other taxonomies, such as …

A phase 1 study of lucatumumab, a fully human anti‐CD 40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple …

…, S Durrant, PS Becker, B Ewald, S Bilic… - British journal of …, 2012 - Wiley Online Library
In this open‐label, multicentre, phase 1 study a fully human anti‐ CD 40 antagonist monoclonal
antibody, lucatumumab, was evaluated in patients with relapsed/refractory multiple …

[HTML][HTML] Prognostic gene expression signature for high-grade serous ovarian cancer

…, H Shirley, C Ball, C Young, S Viduka, H Tran, S Bilic… - Annals of oncology, 2020 - Elsevier
Background Median overall survival (OS) for women with high-grade serous ovarian cancer
(HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-…

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor

KP Papadopoulos, R Isaacs, S Bilic, K Kentsch… - Cancer chemotherapy …, 2015 - Springer
… Following discontinuation of TAS266, the patient’s liver enzyme levels returned to grade 1,
but … This patient’s liver function tests also remained normal throughout the treatment period. At …

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

…, J Rediske, S Bilic, J Dey, J Baeck, S O'Brien - Leukemia & …, 2012 - Taylor & Francis
Lucatumumab is a fully humanized anti-CD40 antibody that blocks interaction of CD40L
with CD40 and also mediates antibody-dependent cell-mediated cytotoxicity (ADCC). We …

Structure of dark triad dirty dozen across eight world regions

…, R Ardi, KA Atitsogbe, S Baltatescu, S Bilić… - …, 2021 - journals.sagepub.com
The Dark Triad (ie, narcissism, psychopathy, Machiavellianism) has garnered intense
attention over the past 15 years. We examined the structure of these traits’ measure—the Dark …

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

HA Huet, JD Growney, JA Johnson, J Li, S Bilic… - MAbs, 2014 - Taylor & Francis
Multiple therapeutic agonists of death receptor 5 (DR5) have been developed and are under
clinical evaluation. Although these agonists demonstrate significant anti-tumor activity in …